secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001213900-26-033878
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences cuts staff, initiates strategic alternatives review; severance costs $51K
--------------------------------------------------------------------------------

- Reduced headcount on March 19, 2026; expects ~$51K in severance charges in Q1 2026.
- Board initiated review of strategic alternatives including mergers, asset sales, or sale of company.
- Engaged Lucid Capital Management as financial advisor and K&L Gates as legal counsel.
- No timetable set for process; will continue executing TAEUS business priorities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026033878/0001213900-26-033878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026033878/ea0283331-8k_endra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-033878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer